title: Glial cell line-derived neurotrophic factor concentration dependently improves disability and motor activity in MPTP-treated common marmosets.
abstract: Glial cell line-derived neurotrophic factor (GDNF) has previously reduced motor deficits and preserved nigral dopamine neurones in rhesus monkeys with a unilateral MPTP-induced lesion of substantia nigra. We now report on the ability of GDNF to reverse motor deficits induced by parenteral administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to common marmosets resulting in bilateral degeneration of the nigrostriatal pathway. Prior to GDNF administration, all MPTP-treated animals showed akinesia or bradykinesia, rigidity, postural instability and tremor. Intraventricular injection of GDNF (10, 100 or 500 microg) at 9 and 13 weeks post MPTP treatment resulted in a concentration dependent improvement in locomotor activity and motor disability which became significant after administration of 100 and 500 microg of GDNF. The most prominent improvements were in alertness, checking movements, and posture. It is concluded that intraventricular GDNF administration improves bilateral Parkinsonian motor disability following MPTP treatment and this may reflect an action of GDNF on remaining nigral dopaminergic neurones.
authors.affiliation: Neurodegenerative Disease Research Centre, Hodgkin Building, GKT School of Biomedical Sciences, King's College London, Guy's Campus, SE1 1UL, London, UK.
authors.forename: S
authors.initials: S
authors.lastname: Costa
authors.forename: M M
authors.initials: MM
authors.lastname: Iravani
authors.forename: R K
authors.initials: RK
authors.lastname: Pearce
authors.forename: P
authors.initials: P
authors.lastname: Jenner
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D000818:Animals; D002144:Callithrix; D015259:Dopamine Agents; D004353:Drug Evaluation, Preclinical; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D019957:Motor Skills Disorders / Q000139:chemically induced / Q000188:drug therapy*; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D018696:Neuroprotective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D010300:Parkinson Disease / Q000188:drug therapy; D013378:Substantia Nigra / Q000187:drug effects / Q000502:physiology
chemical_list: D015259:Dopamine Agents; D051100:Glial Cell Line-Derived Neurotrophic Factor; D009414:Nerve Growth Factors; D009419:Nerve Tissue Proteins; D018696:Neuroprotective Agents; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine